34
Participants
Start Date
March 31, 2012
Primary Completion Date
January 31, 2015
Study Completion Date
January 31, 2018
Brentuximab Vedotin
2 doses administered 14 days apart; followed by combination therapy with AVD for 4-6 cycles; 1.2 mg/kg
Adriamycin, vinblastine, and dacarbazine
Combination therapy with brentuximab for 4-6 cycles; 25 mg/m2 Adriamycin; 6 mg/m2 Vinblastine; 375 mg/m2 Dacarbazine
Moffitt Cancer Center, Tampa
Massachusetts General Hosptial, Boston
Dana-Farber Cancer Institute, Boston
Beth Israel Deaconess Medical Center, Boston
Beth Israel Deaconess Medical Center
OTHER
Dana-Farber Cancer Institute
OTHER
H. Lee Moffitt Cancer Center and Research Institute
OTHER
Seagen Inc.
INDUSTRY
Massachusetts General Hospital
OTHER